The impact of ObamaCare on doctors and patients, companies inside and outside the health sector, and American workers and taxpayers
The Obama administration and leading members of Congress are clashing over a new Medicare payment rule that could compromise patient care, impede development of a fledgling part of the biologics industry, and make it more difficult to track patient safety issues. At issue is government payment policy for a new class of drugs called “biosimilars”—drugs that are similar but not identical to the original brand name biologic drug.
Gallup’s latest poll shows the majority of Americans still oppose the ACA, even two years after its full implementation. Those who are uninsured oppose the health care law by nearly 30 points.
Proponents of more than doubling the current minimum wage of $7.25 appeared to have overlooked a simple fact. Thanks to government mandates such as Obamacare, today’s minimum wage already effectively amounts to $10.46 an hour. If we more than double the nominal minimum wage to $15, we actually will be requiring employers to pay $18.31 an hour.
This week on “The Journal Editorial Report” with Paul Gigot, columnist Kim Strassel talks about how ObamaCare helped the GOP pick up a governor’s seat in Kentucky as the law’s troubled co-ops continue to collapse.
Dr. Christina Bovelsky runs Peachtree Family Medicine in Middletown Delaware, and offers a unique approach to medicine. Rather than dealing with traditional insurance, co-pays and deductibles, Dr. Bovelsky’s patients pay a one-year membership fee. This fee includes between two and four office visits, an annual physical exam, and small procedures like electrocardiograms and strep tests.
Add 250 New York cancer patients to the long list of victims of ObamaCare’s lies — just one more snapshot of the program’s ongoing death spiral.
These New Yokers are getting treatment at world-renowned Memorial Sloan-Kettering Cancer Center — but their ObamaCare policies are about to vanish, as Health Republic, one of the largest health insurers on New York state’s exchange, and the only one to cover Sloan-Kettering treatment, is shutting down at month’s end after losing $130 million.
A local family that bought what they thought was a premium plan discovered they were going to have to pay thousands of dollars per year out of pocket for what other insurance plans would have covered.
In most states, consumers with HIV or AIDS who buy silver-level plans on the insurance marketplaces find limited coverage of common drug regimens they may need and high out-of-pocket costs, according to a new analysis.
Vermont’s top financial regulator has no regrets about being the nation’s only state insurance commissioner to refuse to license an Obamacare co-operative. Susan L. Donegan was commissioner for Vermont’s Division of Insurance in 2013 when she refused to issue a license to the proposed Vermont Health CO-OP, saying it failed to meet state standards. Her action barred the Obamacare non-profit from selling health insurance in the state.
In late September, the handful of CEOs leading Affordable Care Act-funded consumer operated and oriented plans traveled to Denver in search of answers. The past year had been a difficult one. Their companies were struggling, awash in red ink and facing a mounting list of operational challenges. A few co-ops had already shut down, and regulators were circling several more. The fledgling health insurers needed more support from the Centers for Medicare & Medicaid Services if they were going to survive. Most importantly, they needed a lot more money.